Repository logoRepository logo
GRO
  • GRO.data
  • GRO.plan
Help
  • English
  • Deutsch
Log In
New user? Click here to register.Have you forgotten your password?
Publications
Researcher
Organizations
Other
  • Journals
  • Series
  • Events
  • Projects
  • Working Groups

Browsing by Author "Bourenkov, Gleb P."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Results Per Page
  • Sort Options
  • Some of the metrics are blocked by your 
    consent settings
    CASK functions as a Mg2+-independent neurexin kinase
    (Cell Press, 2008)
    Mukherjee, Konark
    ;
    Sharma, Manu
    ;
    Urlaub, Henning  
    ;
    Bourenkov, Gleb P.
    ;
    Jahn, Reinhard  
    ;
    Suedhof, Thomas C.
    ;
    Wahl, Markus C.  
    CASK is a unique MAGUK protein that contains an N-terminal CaM-kinase domain besides the typical MAGUK domains. The CASK CaM-kinase domain is presumed to be a catalytically inactive pseudokinase because it lacks the canonical DFG motif required for Mg2+ binding that is thought to be indispensable for kinase activity. Here we show, however, that CASK functions as an active protein kinase even without Mg2+ binding. High-resolution crystal structures reveal that the CASK CaM-kinase domain adopts a constitutively active conformation that binds ATP and catalyzes phosphotransfer without Mg2+. The CASK CaM-kinase domain phosphorylates itself and at least one physiological interactor, the synaptic protein neurexin-1, to which CASK is recruited via its PDZ domain. Thus, our data indicate that CASK combines the scaffolding activity of MAGUKs with an unusual kinase activity that phosphorylates substrates recuited by the scaffolding activity. Moreover, our study suggests that other pseudokinases (10% of the kinome) could also be catalytically active.
  • Some of the metrics are blocked by your 
    consent settings
    The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design
    (2016)
    Schrader, Jil
    ;
    Henneberg, Fabian
    ;
    Mata, Ricardo A.  
    ;
    Tittmann, Kai  
    ;
    Schneider, Thomas R.
    ;
    Stark, Holger  
    ;
    Bourenkov, Gleb P.
    ;
    Chari, Ashwin
    The proteasome is a validated target for anticancer therapy, and proteasome inhibition is employed in the clinic for the treatment of tumors and hematological malignancies. Here, we describe crystal structures of the native human 20S proteasome and its complexes with inhibitors, which either are drugs approved for cancer treatment or are in clinical trials. The structure of the native human 20S proteasome was determined at an unprecedented resolution of 1.8 angstroms. Additionally, six inhibitor-proteasome complex structures were elucidated at resolutions between 1.9 and 2.1 angstroms. Collectively, the high-resolution structures provide new insights into the catalytic mechanisms of inhibition and necessitate a revised description of the proteasome active site. Knowledge about inhibition mechanisms provides insights into peptide hydrolysis and can guide strategies for the development of next-generation proteasome-based cancer therapeutics.

About

About Us
FAQ
ORCID
End User Agreement
Privacy policy
Cookie consent
Imprint

Contact

Team GRO.publications
support-gro.publications@uni-goettingen.de
Matrix Chat: #support_gro_publications
Feedback

Göttingen Research Online

Göttingen Research Online bundles various services for Göttingen researchers:

GRO.data (research data repository)
GRO.plan (data management planning)
GRO.publications (publication data repository)
Logo Uni Göttingen
Logo Campus Göttingen
Logo SUB Göttingen
Logo eResearch Alliance

Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution 4.0 International license.